Denali_MTNPeak@3x.png
Denali_MTNPeak@3x.png

DEVELOP


The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier.  Our core portfolio currently consists of six programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease.

SCROLL DOWN

DEVELOP


The programs in our portfolio are based on our deep expertise in the biology of neurodegenerative diseases and the blood-brain barrier.  Our core portfolio currently consists of six programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients by directly addressing a cause or risk factor for the disease.

PIPELINE

 

In developing our programs, we rigorously follow three principles


GENETIC PATHWAY POTENTIAL

Each program is addressing a target or pathway that is genetically validated to cause or increase the risk for neurodegenerative diseases.

 

ENGINEERING BRAIN DELIVERY

Each product candidate is designed  to optimize therapeutic exposure in the brain.

 

BIOMARKER-DRIVEN DEVELOPMENT

The development path of each program is enabled by biomarkers to monitor early effects of the drug and select the right patients and the right dose in clinical development.